Factors predisposing to bacterial invasion and infection (Q34579861)

3 August 2017

1 reference

title

Factors predisposing to bacterial invasion and infection (English)

1 reference

3 August 2017

Michael Heinzelmann

1

1 reference

3 August 2017

Melanie Scott

series ordinal

2

1 reference

3 August 2017

Tina Lam

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

The American Journal of Surgery

3 August 2017

published in

1 reference

3 August 2017

volume

183

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

179-190

1 reference

The mechanism by which microorganisms avoid complement attack

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Sepsis and evolution of the innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The Toll receptor family and microbial recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The walk-in anergic patient. How best to assess the risk of sepsis following elective surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

In vivo and in vitro humoral immunity in surgical patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Clinical outcome of seriously ill surgical patients with intra-abdominal infection depends on both physiologic (APACHE II score) and immunologic (DTH score) alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Delayed hypersensitivity skin testing does not influence the management of surgical patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Early decrease in surface expression of HLA-DQ predicts the development of infection in trauma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Microsatellite marker of interferon-gamma receptor 1 gene correlates with infection following major trauma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The pathophysiology of tumor necrosis factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The role of interleukin-1 in disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The molecular basis of T helper 1 and T helper 2 cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Interactions of bacteria with non-phagocytic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Endotoxin and muramyl dipeptide modulate surface receptor expression on human mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

LPS induction of gene expression in human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Superantigens: bacterial and viral proteins that manipulate the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Immunity to intracellular bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Inactivation of antibiotics and the dissemination of resistance genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Prevention of drug access to bacterial targets: permeability barriers and active efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Resistance to antibiotics mediated by target alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

CDC guidelines for the prevention and control of nosocomial infections. Guideline for handwashing and hospital environmental control, 1985. Supersedes guideline for hospital environmental control published in 1981

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Continuous, 10-year wound infection surveillance. Results, advantages, and unanswered questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The epidemiology of wound infection. A 10-year prospective study of 62,939 wounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Identifying patients at high risk of surgical wound infection. A simple multivariate index of patient susceptibility and wound contamination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The importance of tissue antibiotic activity in the prevention of operative wound infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

THE DELAYED CLOSURE OF CONTAMINATED WOUNDS: A PRELIMINARY REPORT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The handling of contaminated abdominal wounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Topical antibiotic and delayed primary closure in the management of contaminated surgical incisions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Delayed primary wound closure in gangrenous and perforated appendicitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Closure of abdominal incisions with subcutaneous catheters. A prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Infections and diabetes: mechanisms and prospects for prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Reduction of operative morbidity and mortality by combined preoperative and postoperative nutritional support

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Effects of immune-enhancing diets on infectious morbidity and multiple organ failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Comparison of the effector cells in human spontaneous cellular cytotoxicity and antibody-dependent cellular cytotoxicity: differential sensitivity of effector cells to in vivo and in vitro corticosteroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Glucocorticoids and immune function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Infectious risk factors in the immunosuppressed host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Comparison of trauma assessment scores and their use in prediction of infection and death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Surgical wound infections: an overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

More is better. Antibiotic management after hemorrhagic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Surgeons, surgery, and immunomodulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Intra-abdominal sepsis: the role of surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

IMMUNIZATION AGAINST MALARIA: VACCINATION OF DUCKS WITH KILLED PARASITES INCORPORATED WITH ADJUVANTS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

A controlled trial of HA-1A in a canine model of gram-negative septic shock.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Monoclonal antibody to TNF in severe septic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

Efficacy and safety of recombinant human activated protein C for severe sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900866-2

10.1016/S0002-9610(01)00866-2

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference